文献速递胃肠外科

淋巴结清扫对局部晚期食管鳞癌新辅助放化疗后生存的影响:NEOCRTEC5010随机多中心研究结果

Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
PubMed 文献 · Ann Surg · 2023-01-10

该研究为NEOCRTEC5010试验的二次分析,比较新辅助放化疗后手术与单纯手术的局部晚期食管鳞癌患者。新辅助放化疗组中,淋巴结清扫数目越多与总生存和无病生存显著改善相关,且未增加术后并发症;清扫少于20枚与局部复发和总复发率显著升高相关。

要点

  • 新辅助放化疗组淋巴结清扫数目增多与总生存和无病生存显著改善相关。
  • 淋巴结清扫少于20枚与局部复发率18.8%对5.2%及总复发率41.2%对25.8%显著升高相关。
  • 系统性淋巴结清扫未增加术后并发症,应作为新辅助放化疗后手术的组成部分。

核心结论

  • 新辅助放化疗后系统性淋巴结清扫不增加手术风险,且与更好的生存和局部疾病控制相关。
  • 系统性淋巴结清扫仍应被视为食管鳞癌新辅助放化疗后手术的组成部分。

研究设计与样本

  • NEOCRTEC5010随机多中心试验的二次分析,比较新辅助放化疗后手术与单纯手术 for 局部晚期食管鳞癌。
  • 在新辅助放化疗组中分析淋巴结清扫数目与围手术期、复发和生存结局的关系。

主要发现

  • 新辅助放化疗组3年总生存显著优于单纯手术组(75.2% vs 61.5%;P=0.011)。
  • 新辅助放化疗组中,淋巴结清扫数目越多与总生存显著改善相关( hazard ratio 0.358;P<0.001)。
  • 淋巴结清扫数目越多与无病生存显著改善相关(hazard ratio 0.415;P=0.001),且对术后并发症无负面影响。
  • 淋巴结清扫少于20枚与局部复发率(18.8% vs 5.2%,P=0.004)和总复发率(41.2% vs 25.8%,P=0.027)显著升高相关。
  • 与持续淋巴结病变患者相比,完全缓解且淋巴结清扫≥20枚的患者生存显著更好,而淋巴结清扫<20枚者无此获益。

关键数值与推荐

  • 淋巴结清扫<20枚 vs ≥20枚:局部复发率18.8% vs 5.2%(P=0.004)。
  • 淋巴结清扫<20枚 vs ≥20枚:总复发率41.2% vs 25.8%(P=0.027)。
  • 淋巴结清扫数目与总生存:hazard ratio 0.358(P<0.001)。
  • 淋巴结清扫数目与无病生存:hazard ratio 0.415(P=0.001)。

临床怎么用

  • 局部晚期食管鳞癌新辅助放化疗后手术中应行系统性淋巴结清扫,目标清扫数目≥20枚。
  • 系统性淋巴结清扫未增加术后并发症,可作为安全的手术组成部分。

局限性

  • 本文为NEOCRTEC5010试验的二次分析,非预设主要终点分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To clarify whether systemic LND influences the safety of surgery and the survival of patients with locally advanced esophageal squamous cell carcinoma (ESCC) after neoadjuvant chemoradiotherapy (nCRT). SUMMARY OF BACKGROUND DATA: Prognostic impact of systemic lymphadenectomy during surgery after nCRT for ESCC is still uncertain and requires clarification. METHODS: This is a secondary analysis of NEOCRTEC5010 trial which compared nCRT followed by surgery versus surgery alone for locally advanced ESCC. Relationship between number of LND and perioperative, recurrence, and survival outcomes were analyzed in the nCRT group. RESULTS: Three-year overall survival was significantly better in the nCRT group than the S group (75.2% vs 61.5%; P = 0.011). In the nCRT group, greater number of LND was associated with significantly better overall survival (hazard ratio, 0.358; P < 0.001) and disease-free survival (hazard ratio, 0.415; P = 0.001), but without any negative impact on postoperative complications. Less LND (<20 vs ≥20) was significantly associated with increased local recurrence (18.8% vs 5.2%, P = 0.004) and total recurrence rates (41.2% vs 25.8%, P = 0.027). Compared to patients with persistent nodal disease, significantly better survival was seen in patients with complete response and with LND ≥20, but not in those with LND <20. CONCLUSIONS: Systemic LND does not increase surgical risks after nCRT in ESCC patients. And it is associated with better survival and local diseasecontrol. Therefore, systemic lymphadenectomy should still be considered as an integrated part of surgery after nCRT for ESCC.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Guo X, Wang Z, Yang H, et al. Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study. Ann Surg. 2023. PMID: 33605586. doi:10.1097/SLA.0000000000004798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。